Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Galcanezumab in Chronic Cluster Headache
2014-005429-11Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cluster Headache (CH) comparing Galcanezumab with Placebo (2 arms). Primary endpoint: Change in weekly cluster headache attack frequency. Started Apr 2015; status: completed.
02
Drugs
galcanezumab
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on 2014-005429-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005429-11.